EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss of $0.62, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. FIX
8. BE
9. AXP
10. NDAQ

Go back to EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss of $0.62, Revenues Beat

EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

September 12, 2018 6:00 AM EDT

-Substantial progress made in the Companys accelerated transformation into a commercial entity

-YUTIQ PDUFA date of November 5, 2018

-Commercial preparations underway for launch of DEXYCU in the first half of calendar year 2019

-Balance sheet strengthened by $35 million of capital led by EW Healthcare Partners

-Conference call and webcast today, September 12th, at 8:30 AM ET-

WATERTOWN, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and... More